NASDAQ:ELDN
Eledon Pharmaceuticals, Inc. Stock News
$2.44
+0.0300 (+1.24%)
At Close: May 06, 2024
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
04:05pm, Wednesday, 29'th Nov 2023
IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
04:05pm, Wednesday, 08'th Nov 2023
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present a poster at the American Society of Nephrol
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Wednesday, 20'th Sep 2023
IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Per
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
08:00am, Friday, 02'nd Jun 2023
IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript
01:03pm, Friday, 12'th May 2023
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Of
Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript
08:28pm, Thursday, 30'th Mar 2023
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
04:05pm, Thursday, 23'rd Mar 2023
Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
04:05pm, Wednesday, 08'th Feb 2023
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the
Eledon Pharmaceuticals, Inc. (ELDN) Q3 2022 Earnings Call Transcript
08:35pm, Monday, 14'th Nov 2022
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Paul Little – Chief Financial Officer David-Alexandre Gros – Chief Ex
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
04:05pm, Thursday, 22'nd Sep 2022
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
08:00am, Monday, 29'th Aug 2022
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferenc
Eledon Pharmaceuticals, Inc. (ELDN) CEO David-Alexandre Gros on Q2 2022 Results - Earnings Call Transcript
09:33pm, Thursday, 11'th Aug 2022
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Paul Little - CFO David-Alexandre Gros - CEO Steve Perrin - President and C
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
09:00am, Monday, 01'st Aug 2022 GlobeNewswire Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 10'th Jun 2022 GlobeNewswire Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development
